ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Design of a highly potent GLP-1R and GCGR dual-agonist for recovering hepatic fibrosis

Song, Nazi; Xu, Hongjiao; Liu, Jiahua; Zhao, Qian; Chen, Hui; Yan, Zhibin; Yang, Runling; Luo, Zhiteng; Liu, Qi; Ouyang, Jianmei; Wu, Shuohan; Luo, Suijia; Ye, Shuyin; Lin, Runfeng; Sun, Xi; Xie, Junqiu; Lan, Tian; Wu, Zhongdao*; Wang, Rui*; Jiang, Xianxing*广东药学院; 兰州大学; 中国医学科学院; 中山大学
Acta Pharmaceutica Sinica B2022-5DOI: 10.1016/j.apsb.2021.12.016
9被引8阅读
引用收藏
分享

摘要

Currently, there is still no effective curative treatment for the development of late-stage liver fibrosis. Here, we have illustrated that TB001, a dual glucagon-like peptide-1 receptor/glucagon receptor (GLP-1R/GCGR) agonist with higher affinity towards GCGR, could retard the progression of liver fibrosis in various rodent models, with remarkable potency, selectivity, extended half-life and low toxicity. Four types of liver fibrosis animal models which were induced by CCl4, alpha-naphthyl-isothiocy-anate (ANIT), bile duct ligation (BDL) and Schistosoma japonicum were used in our study. We found that TB001 treatment dose-dependently significantly attenuated liver injury and collagen accumulation in these animal models. In addition to decreased levels of extracellular matrix (ECM) accumulation during hepatic injury, activation of hepatic stellate cells was also inhibited via suppression of TGF-beta expression as well as downstream Smad signaling pathways particularly in CCl4-and S. japonicum-induced liver fibrosis. Moreover, TB001 attenuated liver fibrosis through blocking downstream activation of proinflammatory nuclear factor kappa B/NF-kappa-B inhibitor alpha (NF kappa B/IKB alpha pathways as well as c-Jun N-terminal kinase (JNK)-dependent induction of hepatocyte apoptosis. Furthermore, GLP-1R and/or GCGR knock-down results represented GCGR played an important role in ameliorating CCl4-induced hepatic fibrosis. Therefore, TB001 can be used as a promising therapeutic candidate for the treatment of multiple causes of hepatic fibrosis demonstrated by our extensive pre-clinical evaluation of TB001.

学科与关键词

关键词
GLP-1RGCGRLiver fibrosisInflammationApoptosisCandidate peptides
相关
加载中…
  • Tyrosine kinase receptor B attenuates liver fibrosis by inhibiting TGF-β/SMAD signaling
    Song, Yu; Wei, Jiayi; Li, Rong; Fu, Ruifeng; Han, Pei; Wang, Heming; Zhang, Guangcong; Li, Shuyu; Chen, Sinuo; Liu, Zhiyong; Zhao, Yicheng; Zhu, Changfeng; Zhu, Jimin; Zhang, Shuncai; Pei, Hao; Cheng, Jiefei; Wu, Jian; Dong, Ling*; Song, Guangqi*; Shen, Xizhong*; Yao, Qunyan*Hepatology, 2023, 78(5): 1433-1447.被引 6
  • Glaucocalyxin A attenuates carbon tetrachloride-induced liver fibrosis and improves the associated gut microbiota imbalance
    Qu, Ru; Zhang, Wang; Ma, Zhuang; Ma, Qianwen; Chen, Mingju; Lan, Tian; Zhou, Lin; Hu, Xuguang*Chemical Biology and Drug Design, 2023, 102(1): 51-64.
  • Ruxolitinib suppresses liver fibrosis progression and accelerates fibrosis reversal via selectively targeting Janus kinase 1/2
    Song, Zhenghui; Liu, Xinhui; Zhang, Wan; Luo, Yue; Xiao, Hua; Liu, Yun; Dai, Guanqi; Hong, Jian*; Li, Aimin*Journal of Translational Medicine, 2022, 20(1): 157.被引 6
查看全部 →

发表信息

论文状态
公开发表
期刊
Acta Pharmaceutica Sinica B
发表日期
2022-05
卷期
第 12 卷, 第 5 期
页码
2443-2461
DOI
10.1016/j.apsb.2021.12.016
期刊收录
CSCD-C.CAST-L
期刊等级
1区
成果收录
SCIE
资助标注
National Natural Science Foundation of China [91853106]; Program for Guangdong Introducing Innovative and Enterpreneurial Teams (China) [2016ZT06Y337]; Guangdong Provincial Key Laboratory of Construction Foundation (China) [2019B030301005]; Shenzhen Science and Technology Program (China) [JSGG20200225153121723]; Fundamental Research Funds for the Central Universities (China) [19ykzd25]; CAMS Innovation Fund for Medical Sciences (CIFMS, China)) [2019-I2M-5-074]

作者

  • S

    Song, Nazi (第一作者)

    sun yat sen univ

  • X

    Xu, Hongjiao

    sun yat sen univ

查看全部 20 位作者收起作者
  • L

    Liu, Jiahua

    sun yat sen univ

  • Z

    Zhao, Qian

    sun yat sen univ

  • C

    Chen, Hui

    sun yat sen univ

  • Y

    Yan, Zhibin

    lanzhou univ · new · chinese acad med sci

  • Y

    Yang, Runling

    lanzhou univ · new · chinese acad med sci

  • L

    Luo, Zhiteng

    sun yat sen univ

  • L

    Liu, Qi

  • O

    Ouyang, Jianmei

  • W

    Wu, Shuohan

    sun yat sen univ

  • L

    Luo, Suijia

  • Y

    Ye, Shuyin

  • L

    Lin, Runfeng

    sun yat sen univ

  • S

    Sun, Xi

    sun yat sen univ

  • X

    Xie, Junqiu

    lanzhou univ · new · chinese acad med sci

  • L

    Lan, Tian

    guangdong pharmaceut univ

  • W

    Wu, Zhongdao (通讯)

    sun yat sen univ

  • W

    Wang, Rui (通讯)

    lanzhou univ · new · chinese acad med sci

  • J

    Jiang, Xianxing (通讯)

    sun yat sen univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417